6cdm › Citations

Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.

Figure 1
Figure 2
Figure 3
Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M, Chen X, Choi CW, Dandey VP, Doria-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD
OpenAccess logo Nat Med 24 857-867 (2018)
Related entries: 5tkj, 5tkk, 6cde, 6cdi, 6cdo, 6cdp

Cited: 175 times
EuropePMC logo PMID: 29867235

Abstract

A central goal of HIV-1 vaccine research is the elicitation of antibodies capable of neutralizing diverse primary isolates of HIV-1. Here we show that focusing the immune response to exposed N-terminal residues of the fusion peptide, a critical component of the viral entry machinery and the epitope of antibodies elicited by HIV-1 infection, through immunization with fusion peptide-coupled carriers and prefusion stabilized envelope trimers, induces cross-clade neutralizing responses. In mice, these immunogens elicited monoclonal antibodies capable of neutralizing up to 31% of a cross-clade panel of 208 HIV-1 strains. Crystal and cryoelectron microscopy structures of these antibodies revealed fusion peptide conformational diversity as a molecular explanation for the cross-clade neutralization. Immunization of guinea pigs and rhesus macaques induced similarly broad fusion peptide-directed neutralizing responses, suggesting translatability. The N terminus of the HIV-1 fusion peptide is thus a promising target of vaccine efforts aimed at eliciting broadly neutralizing antibodies.

Articles - 6cdm mentioned but not cited (1)

  1. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, Chambers M, Chen X, Choi CW, Dandey VP, Doria-Rose NA, Druz A, Eng ET, Farney SK, Foulds KE, Geng H, Georgiev IS, Gorman J, Hill KR, Jafari AJ, Kwon YD, Lai YT, Lemmin T, McKee K, Ohr TY, Ou L, Peng D, Rowshan AP, Sheng Z, Todd JP, Tsybovsky Y, Viox EG, Wang Y, Wei H, Yang Y, Zhou AF, Chen R, Yang L, Scorpio DG, McDermott AB, Shapiro L, Carragher B, Potter CS, Mascola JR, Kwong PD. Nat Med 24 857-867 (2018)


Reviews citing this publication (42)

  1. Recent progress in broadly neutralizing antibodies to HIV. Sok D, Burton DR. Nat Immunol 19 1179-1188 (2018)
  2. Peptide-Based Vaccines: Current Progress and Future Challenges. Malonis RJ, Lai JR, Vergnolle O. Chem Rev 120 3210-3229 (2020)
  3. Antibody responses to viral infections: a structural perspective across three different enveloped viruses. Murin CD, Wilson IA, Ward AB. Nat Microbiol 4 734-747 (2019)
  4. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Haynes BF, Wiehe K, Borrow P, Saunders KO, Korber B, Wagh K, McMichael AJ, Kelsoe G, Hahn BH, Alt F, Shaw GM. Nat Rev Immunol 23 142-158 (2023)
  5. Advancing an HIV vaccine; advancing vaccinology. Burton DR. Nat Rev Immunol 19 77-78 (2019)
  6. Eliciting B cell immunity against infectious diseases using nanovaccines. Singh A. Nat Nanotechnol 16 16-24 (2021)
  7. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. Stephenson KE, Wagh K, Korber B, Barouch DH. Annu Rev Immunol 38 673-703 (2020)
  8. The Conformational States of the HIV-1 Envelope Glycoproteins. Wang Q, Finzi A, Sodroski J. Trends Microbiol 28 655-667 (2020)
  9. Innovations in structure-based antigen design and immune monitoring for next generation vaccines. Ward AB, Wilson IA. Curr Opin Immunol 65 50-56 (2020)
  10. Gene Editing of HIV-1 Co-receptors to Prevent and/or Cure Virus Infection. Allen AG, Chung CH, Atkins A, Dampier W, Khalili K, Nonnemacher MR, Wigdahl B. Front Microbiol 9 2940 (2018)
  11. HIV-1 cell-to-cell transmission and broadly neutralizing antibodies. Dufloo J, Bruel T, Schwartz O. Retrovirology 15 51 (2018)
  12. Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies. Torrents de la Peña A, Sanders RW. Retrovirology 15 63 (2018)
  13. Immune Correlate-Guided HIV Vaccine Design. Alter G, Barouch D. Cell Host Microbe 24 25-33 (2018)
  14. Peptides for Vaccine Development. Hamley IW. ACS Appl Bio Mater 5 905-944 (2022)
  15. HIV vaccinology: 2021 update. Lee JH, Crotty S. Semin Immunol 51 101470 (2021)
  16. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. Derking R, Sanders RW. J Int AIDS Soc 24 Suppl 7 e25797 (2021)
  17. HIV/AIDS Vaccines: 2018. Robinson HL. Clin Pharmacol Ther 104 1062-1073 (2018)
  18. Strategies for induction of HIV-1 envelope-reactive broadly neutralizing antibodies. Williams WB, Wiehe K, Saunders KO, Haynes BF. J Int AIDS Soc 24 Suppl 7 e25831 (2021)
  19. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth. van Schooten J, van Gils MJ. Retrovirology 15 74 (2018)
  20. HIV-1 cure strategies: why CRISPR? Atkins AJ, Allen AG, Dampier W, Haddad EK, Nonnemacher MR, Wigdahl B. Expert Opin Biol Ther 21 781-793 (2021)
  21. Strategies for inducing effective neutralizing antibody responses against HIV-1. Del Moral-Sánchez I, Sliepen K. Expert Rev Vaccines 18 1127-1143 (2019)
  22. Neutralizing Antibodies Targeting HIV-1 gp41. Caillat C, Guilligay D, Sulbaran G, Weissenhorn W. Viruses 12 E1210 (2020)
  23. Broadly neutralizing antibodies and vaccine design against HIV-1 infection. Wang Q, Zhang L. Front Med 14 30-42 (2020)
  24. Humoral Immunity to Hantavirus Infection. Engdahl TB, Crowe JE. mSphere 5 e00482-20 (2020)
  25. Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases. Yenkoidiok-Douti L, Jewell CM. ACS Biomater Sci Eng 6 759-778 (2020)
  26. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines. Guo L, Lin S, Chen Z, Cao Y, He B, Lu G. Signal Transduct Target Ther 8 197 (2023)
  27. Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. Finney J, Kelsoe G. Retrovirology 15 53 (2018)
  28. Ending the Human Immunodeficiency Virus Pandemic: Optimizing the Prevention and Treatment Toolkits. Eisinger RW, Folkers GK, Fauci AS. Clin Infect Dis 69 2212-2217 (2019)
  29. Current progress in the development of prophylactic and therapeutic vaccines. Li T, Qian C, Gu Y, Zhang J, Li S, Xia N. Sci China Life Sci 66 679-710 (2023)
  30. Peptide-Based Vaccination for Antibody Responses Against HIV. Combadière B, Beaujean M, Chaudesaigues C, Vieillard V. Vaccines (Basel) 7 E105 (2019)
  31. A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target. Parker Miller E, Finkelstein MT, Erdman MC, Seth PC, Fera D. Viruses 13 1774 (2021)
  32. How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika. Abernathy ME, Dam KA, Esswein SR, Jette CA, Bjorkman PJ. Viruses 13 2106 (2021)
  33. Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire. Finney J, Watanabe A, Kelsoe G, Kuraoka M. Immunol Rev 292 24-36 (2019)
  34. Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development? Das S, Kumar R, Ahmed S, Parray HA, Samal S. Ther Adv Vaccines Immunother 8 2515135520957763 (2020)
  35. HIV-1 Envelope Conformation, Allostery, and Dynamics. Bennett AL, Henderson R. Viruses 13 852 (2021)
  36. Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. Wilmschen S, Schmitz JE, Kimpel J. Vaccines (Basel) 7 E119 (2019)
  37. A Zigzag but Upward Way to Develop an HIV-1 Vaccine. Wen Z, Sun C. Vaccines (Basel) 8 E511 (2020)
  38. Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies. Liu Q, Zhang P, Lusso P. Viruses 13 1405 (2021)
  39. Discovery medicine - the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine. Martin TM, Robinson ST, Huang Y. Curr Opin HIV AIDS 18 290-299 (2023)
  40. Guiding HIV-1 vaccine development with preclinical nonhuman primate research. Counts JA, Saunders KO. Curr Opin HIV AIDS 18 315-322 (2023)
  41. Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies. Zhou JO, Ton T, Morriss JW, Nguyen D, Fera D. AIDS Res Hum Retroviruses 34 760-768 (2018)
  42. [Development approaches for vaccines against hepatitis C virus infections]. Bankwitz D, Krey T, Pietschmann T. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 65 183-191 (2022)

Articles citing this publication (132)



Quick links